Fenofibrate cardioprotective, cuts risk of death in T2D
In patients with type 2 diabetes (T2D), treatment with fenofibrate appears to lower the incidence of cardiovascular events, as well as the rate of total and cardiac mortality, according to data from a large study.
Fenofibrate cardioprotective, cuts risk of death in T2D
01 Jul 2021